LAUSR

Low ‐ grade ovarian cancer (LGOC) comprises a rare group of tumors, including serous, mucinous, and endometrioid subtypes, that collectively account for 10% of ovarian cancer (OC) deaths and are histologically and molecularly distinct from high ‐ grade serous OC, the most common and aggressive type of OC. 1 Low ‐ grade serous OC (LGSC) is the prototypic form of LGOC, representing 5%–10% of all OC cases. Patients with LGOC generally have disease that is slower growing but also less responsive to chemotherapy. Prior studies have shown that patients with LGSC have response rates to first ‐ line neoadjuvant chemotherapy ranging from 4% to 23%. 2,3 Given the modest response rates seen with chemotherapy, there has been a recent focus on the devel-opment of targeted therapeutics for the treatment of this disease (Figure 1). The vast majority of LGSCs express the estrogen receptor (ER) by immunohistochemistry (IHC; 87% ER ‐ positive) and to a lesser extent, the progesterone receptor (PR; 58